{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:37:01Z","timestamp":1774046221236,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12325-021-01984-4","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T02:02:52Z","timestamp":1638410572000},"page":"674-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-World Safety and Effectiveness of Canagliflozin Treatment for Type\u00a02 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance"],"prefix":"10.1007","volume":"39","author":[{"given":"Nobuya","family":"Inagaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5267-8284","authenticated-orcid":false,"given":"Kazuyo","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7353-4201","authenticated-orcid":false,"given":"Kazumi","family":"Mori-Anai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koume","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"1984_CR1","unstructured":"Mitsubishi Tanabe Pharma Corporation. [CANAGLU\u00ae 100 mg tablets. revised June 2019] https:\/\/medical.mt-pharma.co.jp\/di\/file\/dc\/can_a.pdf. Accessed 8 June 2021 (In Japanese)."},{"issue":"8","key":"1984_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/14656566.2018.1473378","volume":"19","author":"N Inagaki","year":"2018","unstructured":"Inagaki N, Harashima SI, Iijima H. Canagliflozin for the treatment of type\u00a02 diabetes: a comparison between Japanese and non-Japanese patients. Expert Opin Pharmacother. 2018;19(8):895\u2013908. https:\/\/doi.org\/10.1080\/14656566.2018.1473378.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1984_CR3","first-page":"499","volume":"46","author":"N Inagaki","year":"2018","unstructured":"Inagaki N, Nangaku M, Sakata Y, et al. Safety and efficacy of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, as monotherapy and in combination with antidiabetic agents in patients with type 2 diabetes mellitus \u2013 an interim analysis of post-marketing surveillance (SAPPHIRE). Jpn Pharmacol Ther. 2018;46(4):499\u2013519 (In Japanese).","journal-title":"Jpn Pharmacol Ther"},{"issue":"1","key":"1984_CR4","first-page":"9","volume":"68","author":"N Inagaki","year":"2019","unstructured":"Inagaki N, Nangaku M, Sakata Y, et al. Safety and efficacy of canagliflozin, an SGLT2 inhibitor, in patients with type 2 diabetes mellitus \u2013 an interim analysis of post-marketing surveillance (SAPPHIRE). J New Remed Clin. 2019;68(1):9\u201337 (In Japanese).","journal-title":"J New Remed Clin"},{"issue":"3","key":"1984_CR5","first-page":"288","volume":"69","author":"N Inagaki","year":"2020","unstructured":"Inagaki N, Nangaku M, Sakata Y, Sasaki K, Nakamura H, Hamada K. Safety and efficacy of canagliflozin, an SGLT2 inhibitor, in patients with type 2 diabetes mellitus \u2013 the interim analysis of post-marketing surveillance (SAPPHIRE), third report. J New Remed Clin. 2020;69(3):288\u2013329 (In Japanese).","journal-title":"J New Remed Clin"},{"key":"1984_CR6","doi-asserted-by":"publisher","unstructured":"Committee on the Proper Use of SGLT2 Inhibitors. Recommendations on the proper use of SGLT2 inhibitors. J Diabetes Investig. 2020;11(1):257\u201361. https:\/\/doi.org\/10.1111\/jdi.13160.","DOI":"10.1111\/jdi.13160"},{"key":"1984_CR7","unstructured":"Committee on the Proper Use of SGLT2 Inhibitors. Recommendations for proper use of SGLT2 inhibitors. Revised December 25, 2020. http:\/\/www.fa.kyorin.co.jp\/jds\/uploads\/recommendation_SGLT2.pdf. Accessed January 29, 2021. (In Japanese)."},{"issue":"2","key":"1984_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/03007995.2017.1392293","volume":"34","author":"M Goda","year":"2018","unstructured":"Goda M, Yamakura T, Sasaki K, Tajima T, Ueno M. Safety and efficacy of canagliflozin in elderly patients with type\u00a02 diabetes mellitus: a 1-year post-marketing surveillance in Japan. Curr Med Res Opin. 2018;34(2):319\u201327. https:\/\/doi.org\/10.1080\/03007995.2017.1392293.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1984_CR9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/dom.12348","volume":"16","author":"JF Yale","year":"2014","unstructured":"Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type\u00a02 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016\u201327. https:\/\/doi.org\/10.1111\/dom.12348.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1984_CR10","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/dom.12149","volume":"15","author":"N Inagaki","year":"2013","unstructured":"Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type\u00a02 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15(12):1136\u201345. https:\/\/doi.org\/10.1111\/dom.12149.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1984_CR11","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1517\/14656566.2014.935764","volume":"15","author":"N Inagaki","year":"2014","unstructured":"Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type\u00a02 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled phase III study. Expert Opin Pharmacother. 2014;15(11):1501\u201315. https:\/\/doi.org\/10.1517\/14656566.2014.935764.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"1984_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/jdi.12266","volume":"6","author":"N Inagaki","year":"2015","unstructured":"Inagaki N, Kondo K, Yoshinari T, Kuki H. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type\u00a02 diabetes: a 52-week open-label study. J Diabetes Investig. 2015;6(2):210\u20138. https:\/\/doi.org\/10.1111\/jdi.12266.","journal-title":"J Diabetes Investig"},{"key":"1984_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12933-016-0407-4","volume":"15","author":"N Inagaki","year":"2016","unstructured":"Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type\u00a02 diabetes mellitus. Cardiovasc Diabetol. 2016;15:89. https:\/\/doi.org\/10.1186\/s12933-016-0407-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1984_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/dom.12898","volume":"19","author":"T Kadowaki","year":"2017","unstructured":"Kadowaki T, Inagaki N, Kondo K, et al. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type\u00a02 diabetes mellitus: results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017;19(6):874\u201382. https:\/\/doi.org\/10.1111\/dom.12898.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1984_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/dom.13038","volume":"20","author":"T Kadowaki","year":"2018","unstructured":"Kadowaki T, Inagaki N, Kondo K, et al. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type\u00a02 diabetes. Diabetes Obes Metab. 2018;20(1):77\u201384. https:\/\/doi.org\/10.1111\/dom.13038.","journal-title":"Diabetes Obes Metab"},{"key":"1984_CR16","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Chapter 1: Definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19\u201362. https:\/\/doi.org\/10.1038\/kisup.2012.64.","DOI":"10.1038\/kisup.2012.64"},{"issue":"6","key":"1984_CR17","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1007\/s10157-018-1615-x","volume":"22","author":"E Kanda","year":"2018","unstructured":"Kanda E, Kashihara N, Matsushita K, et al. Guidelines for clinical evaluation of chronic kidney disease: AMED research on regulatory science of pharmaceuticals and medical devices. Clin Exp Nephrol. 2018;22(6):1446\u201375. https:\/\/doi.org\/10.1007\/s10157-018-1615-x.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"1984_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/14740338.2020.1694659","volume":"19","author":"K Kaku","year":"2020","unstructured":"Kaku K, Chin R, Naito Y, et al. Safety and effectiveness of empagliflozin in Japanese patients with type\u00a02 diabetes: interim analysis from a post-marketing surveillance study. Expert Opin Drug Saf. 2020;19(2):211\u201321. https:\/\/doi.org\/10.1080\/14740338.2020.1694659.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1984_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14656566.2020.1817388","volume":"22","author":"I Nakamura","year":"2021","unstructured":"Nakamura I, Maegawa H, Tobe K, Uno S. Real-world evidence for long-term safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus: final results of a 3-year post-marketing surveillance study (STELLA-LONG TERM). Expert Opin Pharmacother. 2021;22(3):373\u201387. https:\/\/doi.org\/10.1080\/14656566.2020.1817388.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"1984_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/jdi.13333","volume":"12","author":"K Utsunomiya","year":"2021","unstructured":"Utsunomiya K, Koshida R, Kakiuchi S, et al. Safety and effectiveness of tofogliflozin in Japanese patients with type\u00a02 diabetes mellitus treated in real-world clinical practice: results of a 36-month post-marketing surveillance study (J-STEP\/LT). J Diabetes Investig. 2021;12(2):184\u201399. https:\/\/doi.org\/10.1111\/jdi.13333.","journal-title":"J Diabetes Investig"},{"issue":"8","key":"1984_CR21","first-page":"1305","volume":"48","author":"H Hara","year":"2020","unstructured":"Hara H, Kim H, Tokimoto T, Takumi Y. Evaluation of safety and efficacy of dapagliflozin in patients with type\u00a02 diabetes \u2013 a final report of a special drug use-results survey for long-term use (DAHLIA Study). Jpn Pharmacol Ther. 2020;48(8):1305\u201333 (In Japanese).","journal-title":"Jpn Pharmacol Ther"},{"issue":"4","key":"1984_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/1060028020951928","volume":"55","author":"K Engelhardt","year":"2021","unstructured":"Engelhardt K, Ferguson M, Rosselli JL. Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter\u00a02 inhibitors. Ann Pharmacother. 2021;55(4):543\u20138. https:\/\/doi.org\/10.1177\/1060028020951928.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"1984_CR23","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1517\/14656566.2015.1055250","volume":"16","author":"N Inagaki","year":"2015","unstructured":"Inagaki N, Goda M, Yokota S, Maruyama N, Iijima H. Safety and efficacy of canagliflozin in Japanese patients with type\u00a02 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study. Expert Opin Pharmacother. 2015;16(11):1577\u201391. https:\/\/doi.org\/10.1517\/14656566.2015.1055250.","journal-title":"Expert Opin Pharmacother"},{"key":"1984_CR24","doi-asserted-by":"publisher","unstructured":"American Diabetes Association. 11. Microvascular complications and foot care: Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S151\u201367. https:\/\/doi.org\/10.2337\/dc21-S011.","DOI":"10.2337\/dc21-S011"},{"issue":"2","key":"1984_CR25","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s12325-016-0457-8","volume":"34","author":"H Tanaka","year":"2017","unstructured":"Tanaka H, Takano K, Iijima H, et al. Factors affecting canagliflozin-induced transient urine volume increase in patients with type\u00a02 diabetes mellitus. Adv Ther. 2017;34(2):436\u201351. https:\/\/doi.org\/10.1007\/s12325-016-0457-8.","journal-title":"Adv Ther"},{"issue":"6","key":"1984_CR26","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","volume":"62","author":"DR Matthews","year":"2019","unstructured":"Matthews DR, Li Q, Perkovic V, et al. Effects of canagliflozin on amputation risk in type\u00a02 diabetes: the CANVAS Program. Diabetologia. 2019;62(6):926\u201338. https:\/\/doi.org\/10.1007\/s00125-019-4839-8.","journal-title":"Diabetologia"},{"issue":"24","key":"1984_CR27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"key":"1984_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.diabres.2018.01.020","volume":"137","author":"M Iwase","year":"2018","unstructured":"Iwase M, Fujii H, Nakamura U, et al. Incidence of diabetic foot ulcer in Japanese patients with type\u00a02 diabetes mellitus: The Fukuoka diabetes registry. Diabetes Res Clin Pract. 2018;137:183\u20139. https:\/\/doi.org\/10.1016\/j.diabres.2018.01.020.","journal-title":"Diabetes Res Clin Pract"},{"key":"1984_CR29","doi-asserted-by":"publisher","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","DOI":"10.1056\/NEJMoa1611925"},{"key":"1984_CR30","doi-asserted-by":"publisher","unstructured":"Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323\u201334. https:\/\/doi.org\/10.1161\/circulationaha.117.032038.","DOI":"10.1161\/circulationaha.117.032038"},{"issue":"5","key":"1984_CR31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/circulationaha.118.034222","volume":"138","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type\u00a02 diabetes mellitus: results from the CANVAS Program. Circulation. 2018;138(5):458\u201368. https:\/\/doi.org\/10.1161\/circulationaha.118.034222.","journal-title":"Circulation"},{"key":"1984_CR32","doi-asserted-by":"publisher","unstructured":"Doi Y, Ninomiya T, Hata J, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. Stroke. 2010;41(2):203\u20139. https:\/\/doi.org\/10.1161\/strokeaha.109.564708.","DOI":"10.1161\/strokeaha.109.564708"},{"key":"1984_CR33","doi-asserted-by":"publisher","unstructured":"Sone H, Tanaka S, Tanaka S, et al. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type\u00a02 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011;96(11):3448\u201356. https:\/\/doi.org\/10.1210\/jc.2011-0622.","DOI":"10.1210\/jc.2011-0622"},{"key":"1984_CR34","doi-asserted-by":"publisher","unstructured":"Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type\u00a02 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):951\u201364. https:\/\/doi.org\/10.1016\/s2213-8587(17)30327-3.","DOI":"10.1016\/s2213-8587(17)30327-3"},{"issue":"10","key":"1984_CR35","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/j.1464-5491.2011.03347.x","volume":"28","author":"H Yokoyama","year":"2011","unstructured":"Yokoyama H, Matsushima M, Kawai K, et al. Low incidence of cardiovascular events in Japanese patients with type\u00a02 diabetes in primary care settings: a prospective cohort study (JDDM 20). Diabet Med. 2011;28(10):1221\u20138. https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03347.x.","journal-title":"Diabet Med"},{"issue":"12","key":"1984_CR36","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1080\/14740338.2016.1236909","volume":"15","author":"A Offurum","year":"2016","unstructured":"Offurum A, Wagner LA, Gooden T. Adverse safety events in patients with chronic kidney disease (CKD). Expert Opin Drug Saf. 2016;15(12):1597\u2013607. https:\/\/doi.org\/10.1080\/14740338.2016.1236909.","journal-title":"Expert Opin Drug Saf"},{"issue":"18","key":"1984_CR37","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1001\/archinte.160.18.2717","volume":"160","author":"JM Rothschild","year":"2000","unstructured":"Rothschild JM, Bates DW, Leape LL. Preventable medical injuries in older patients. Arch Intern Med. 2000;160(18):2717\u201328. https:\/\/doi.org\/10.1001\/archinte.160.18.2717.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1984_CR38","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/jdi.12644","volume":"8","author":"A Kashiwagi","year":"2017","unstructured":"Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter\u00a02 inhibitors on cardio-renal protection in the treatment of patients with type\u00a02 diabetes mellitus. J Diabetes Investig. 2017;8(4):416\u201327. https:\/\/doi.org\/10.1111\/jdi.12644.","journal-title":"J Diabetes Investig"},{"issue":"12","key":"1984_CR39","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.2337\/dc15-0642","volume":"38","author":"S Mudaliar","year":"2015","unstructured":"Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 2015;38(12):2344\u201353. https:\/\/doi.org\/10.2337\/dc15-0642.","journal-title":"Diabetes Care"},{"issue":"8","key":"1984_CR40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495\u2013502. https:\/\/doi.org\/10.1038\/nrendo.2011.243.","journal-title":"Nat Rev Endocrinol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01984-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01984-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01984-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T08:47:00Z","timestamp":1643359620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01984-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1984"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01984-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"27 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}